caspofungin + liposomal amphotericin B
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hematopoietic Stem Cell Transplantation
Conditions
Hematopoietic Stem Cell Transplantation, Fungus Diseases
Trial Timeline
May 1, 2004 → Dec 1, 2007
NCT ID
NCT00148148About caspofungin + liposomal amphotericin B
caspofungin + liposomal amphotericin B is a phase 2 stage product being developed by Merck for Hematopoietic Stem Cell Transplantation. The current trial status is completed. This product is registered under clinical trial identifier NCT00148148. Target conditions include Hematopoietic Stem Cell Transplantation, Fungus Diseases.
What happened to similar drugs?
1 of 3 similar drugs in Hematopoietic Stem Cell Transplantation were approved
Approved (1) Terminated (1) Active (1)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00148148 | Phase 2 | Completed |
Competing Products
20 competing products in Hematopoietic Stem Cell Transplantation